DaVita Inc. (DVA) Shares Decline Amid Federal Kidney Care Plan Announcement
- Closing price: USD 176.81 (down 6.23 % from the previous 24‑hour period).
- Volume: USD 363.2 million of shares traded in the last 24 hours.
- Shares outstanding: 63.8 million.
- Market capitalization: USD 11.9 billion.
- Simple moving average (200 days): USD 174.04.
- 52‑week range: high USD 247.49 (08 / 03 / 2026); low USD 101.00 (01 / 14 / 2026).
DaVita Inc., a Denver‑based kidney dialysis provider, reported a 6.23 % decline in its stock price during the 24‑hour trading session ending at 11:50 PM Central Europe on Wednesday, 21 March 2026. The decline coincides with the company’s public response to the U.S. Department of Health and Human Services’ Kidney Care National Plan. DaVita reaffirmed its commitment to earlier disease detection, slower disease progression, and expanded patient choice. The company also highlighted the growth of its multispecialty services and the deployment of clinical innovations designed to improve dialysis outcomes and support kidney transplantation.
Market Reaction
Investors reacted negatively to the federal plan, citing concerns over potential regulatory changes and increased competition within the dialysis sector. Consequently, DaVita shares fell during the trading day. The company’s market capitalization is currently USD 11.9 billion, with an average daily trading volume of USD 363.2 million.
Upcoming Events
DaVita will hold a third‑quarter 2026 earnings conference call on 29 October 2026. The call will address the company’s financial results and its strategy for navigating the evolving kidney‑care landscape. The call will be webcast live; analysts wishing to participate must register in advance to receive dial‑in details.
Related Stock Performance (Last 24 Hours)
| Ticker | Change | Current Price (USD) | Market Capitalization (USD) |
|---|---|---|---|
| TRMB (Trimble) | +3.62 % | 62.59 | 14 billion |
| GEN (Gen Digital) | +1.86 % | 24.12 | 14.2 billion |
| PNFP (Pinnacle Financial Partners) | +1.48 % | 98.21 | 14.1 billion |
| COKE (Coca‑Cola) | +1.56 % | 209.69 | 14 billion |
| NBIX (Neurocrine Biosciences) | +3.66 % | 141.31 | 13.9 billion |
Trimble Inc.
Trimble’s shares increased by 3.62 % to USD 62.59. The company announced a third‑quarter 2026 earnings conference call scheduled for 4 November 2026 at 8 a.m. Eastern Time. Trimble is a global technology provider that integrates physical and digital environments across construction, geospatial, and transportation sectors. The company emphasized its commitment to productivity and progress in infrastructure, building design, supply‑chain optimisation, and mapping initiatives.
Gen Digital Inc.
Gen Digital’s shares rose by 1.86 % to USD 24.12. The company’s price‑to‑earnings ratio is 13.83. BIWIN Digital Inc. reported a board resignation: executive Wang Can resigned from his board and vice‑general manager positions but will remain chairman and general manager of its subsidiary, Hangzhou Chip Force Semiconductor Ltd. The change does not affect board size or operational stability. The company maintains a robust research and development team of 1,685 employees, representing approximately 45 % of total staff.
Pinnacle Financial Partners Inc.
Pinnacle’s shares increased by 1.48 % to USD 98.21. The company released its latest quarterly financial results, showing improved earnings per share and revenue compared to the same period in the previous year. Analysts expect the upward trend to continue throughout the fiscal year.
Coca‑Cola Co.
Coca‑Cola’s shares rose by 1.56 % to USD 209.69. The company’s price‑to‑earnings ratio is 28.18.
Neurocrine Biosciences Inc.
Neurocrine’s shares increased by 3.66 % to USD 141.31. The company announced a Phase 2 study of its oral muscarinic agonist, NBI‑567, in adults with mild to moderate Alzheimer’s disease. The randomized, double‑blind, placebo‑controlled trial will enroll approximately 135 participants already receiving an acetylcholinesterase inhibitor, over a 12‑week period. The study will assess safety, tolerability, pharmacokinetics, and cognitive outcomes using a composite neuropsychological test battery and secondary measures of Alzheimer’s disease severity. The study is registered on ClinicalTrials.gov.
DaVita Inc. Overview
DaVita Inc. is headquartered in Denver, Colorado, United States. The company specializes in kidney dialysis services for patients with chronic kidney failure and operates worldwide. DaVita’s website is www.davita.com . DaVita went public on the New York Stock Exchange on 31 October 1995.
